Is everyone ready? Good, then I'll begin. OK. Well, based on average growth in sales over the last two years and given the relatively stable state of the market at the moment as far as competition is concerned, we're forecasting a fairly modest increase in the first quarter, about 2 to 3%. We expect this to rise to between 7 and 10% in the second and third quarters, after the launch of the new slow, release version of the drug. Marketing tells me, thanks, Werner for your help with this. You're welcome. That demand for this version is strong and should be reflected in sales more or less immediately. So that's the basic picture. There are just a couple of monthly variations to this trend which I'll explain now. If you look at the graph, you'll see that in March last year sales went up quite sharply and that the figure predicted for this year is much lower.